1. This presentation is Proprietary and no portion of it may be utilized without the permission of Bio- Investigations Ltd. ENHANCING THE VALUATION OF EXTERNALLY-DERIVED TECHNOLOGY: A SYSTEMS APPROACH Bio-Investigations Ltd. Madison, CT 06443 27 December 2013

2. “ Externally-Derived Technology ” ( EDT) encompasses technology (including service models) identified, patented, and/or developed outside of a major multinational corporation. It ’ s origin may include universities, service providers, biotechnology companies, and/or entities established by prolific Inventors.

3. Sources of EDT may include: University of Connecticut Health Center, Farmington, CT – Center for Science & Technology Commercialization University of Connecticut Health Center, Farmington, CT – Center for Science & Technology Commercialization Inventions of Drs. XX, YY, XZ Inventions of Drs. XX, YY, XZ University of Calgary ’ s UTI University of Calgary ’ s UTI Fox Chase Cancer Center Fox Chase Cancer Center University of Nebraska Medical Center University of Nebraska Medical Center American Imaging, Inc. American Imaging, Inc.

4. What is the Problem? Major multinationals often have fully committed their internal R&D resources and are unable to react to major technologic and market opportunities that involve “ Technology ” and/or business models discovered externally. Major multinationals often have fully committed their internal R&D resources and are unable to react to major technologic and market opportunities that involve “ Technology ” and/or business models discovered externally. The “ not-invented here syndrome ” clouds objectivity in evaluating technology. The “ not-invented here syndrome ” clouds objectivity in evaluating technology.

5. What is the Opportunity? A major objective of Bio-Investigations Ltd. is the identification of, and negotiation for, major Externally Derived Technology, either within the North American continent or on a global basis. A major objective of Bio-Investigations Ltd. is the identification of, and negotiation for, major Externally Derived Technology, either within the North American continent or on a global basis. The existing in-licensing model, and present University connections to bring in EDT by the major multinationals, are not efficient. The existing in-licensing model, and present University connections to bring in EDT by the major multinationals, are not efficient.

6. What Options Exist to Aid In Advancing Externally-Derived Technology? Consortium Approach, Drawing Proactively on Qualified Universities; Consortium Approach, Drawing Proactively on Qualified Universities; Contract Research Organizations; Contract Research Organizations; Clinical Research Organizations; Clinical Research Organizations; Specialized Service Providers (i.e., AI); Specialized Service Providers (i.e., AI); All of the above, Managed by a TCO All of the above, Managed by a TCO

7. Battelle Memorial Institute (http://www.battelle.org), A Contract Research Organization: serves industry and government in developing new technologies and products; serves industry and government in developing new technologies and products; advances each year thousands of technology projects at their various business operations; advances each year thousands of technology projects at their various business operations; is an organization that focuses on contract research and the commercialization of innovative technology. is an organization that focuses on contract research and the commercialization of innovative technology.

8. Clinical Research Organizations are Interacting with Externally-Derived Technology in More Ways Than Most Realize, And Participate in the Valuation Cycle Examples Include: Examples Include: – PAREXEL International Corporation – Covance Inc. – Client Associated Businesses, Inc. – Quintiles Transnational Corporation

9. ADVANCING TECHNOLOGY EXTERNALLY ALLOWS FOR AN INCREASE IN IT ’ S VALUATION

10. Externally-Derived Technology Must Pass A Pre-Defined Scientific Filter to be Advanced Into The Full Assessment Cycle

11. Technical Reviewers Are Specialists In their Respective Areas, And Are Charged to Generate Independent Assessments A Consensus on Scientific and/or Business Merit Allows for Advancement Into: A Consensus on Scientific and/or Business Merit Allows for Advancement Into: –Intellectual Property Review Freedom To Operate Analysis Freedom To Operate Analysis –Market Assessment –Medical Analysis

12. What is the Solution? The identification of key “ Technology ” by Bio-Investigations Ltd. may be successfully leveraged by major multinationals through the utilization of external organizations. The identification of key “ Technology ” by Bio-Investigations Ltd. may be successfully leveraged by major multinationals through the utilization of external organizations. Service providers have the opportunity to participate in increased technology valuation. Service providers have the opportunity to participate in increased technology valuation.

13. The following slides are subsequent to XXXX-related activities, conducted on: Executive Strategy Session, XX, 10 May 20XX; Executive Strategy Session, XX, 10 May 20XX; Database Strategy Session, XX, 26 May 20XX; Database Strategy Session, XX, 26 May 20XX; R&D N.A. Consultation, XX, 26 May 20XX; R&D N.A. Consultation, XX, 26 May 20XX; Bio-Investigations Ltd. Biomarker Filtering Audit Session, CT, 27-30 May 20XX Bio-Investigations Ltd. Biomarker Filtering Audit Session, CT, 27-30 May 20XX

14. The Technology Review Committee will be Comprised of 6 Individuals, all Initially Providing Independent Assessments 2 Members – XXX – XXX 2 Members – XXX – XXX 1 Member – External Expert – U.S. 1 Member – External Expert – U.S. 1 Member – External Expert - Canada 1 Member – External Expert - Canada

15. XXX Biomarker Consortium – A Proposal for Implementation - 1 June 20XX Externally Derived Technology Externally Derived Technology Technology Review Committee GO Decision GO Decision Working Discussion Targeted Toward Clear Decision Working Discussion Targeted Toward Clear Decision GO Decision GO Decision NO-GO Decision NO-GO Decision 0, 1, or 2 Positives NO-GO Decision NO-GO Decision 0, 1, 2, or 3 Positives 4, 5, or 6 Positives 5 or 6 Positives 3 or 4 Positives Commercialization Process Commercialization Process Int. Prop. Analysis Int. Prop. Analysis Market Assessment Market Assessment Medical Analysis Medical Analysis